Business
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
CHICAGO, June 24, 2025--MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/c5d3b46f03e5c2289d733e5ac9ca6fb6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7C6KCl0e.cCqtWA6ovQrDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c5d3b46f03e5c2289d733e5ac9ca6fb6","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/KfkXFclmMH8YYsdcxAqpAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c5d3b46f03e5c2289d733e5ac9ca6fb6","width":1000,"height":380}},"lazy":false},{"type":"text","content":"Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"CHICAGO, June 24, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA’s lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor.","length":590,"tagName":"p"},{"type":"text","content":"As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (CST) in HCC and may participate in future investigator sponsored trials (IST).","length":173,"tagName":"p"},{"type":"text","content":""Drs. Pinato and Fulgenzi are scientific experts on inflammation as a pathogenic and prognostic mechanism in primary liver cancers. Together, their research has focused on improving the treatment of HCC, particularly with the use of anti-cancer immunotherapy," said MAIA Chairman and CEO Vlad Vitoc, M.D. "They will bring a wealth of knowledge to our SAB, with specialized expertise that will inform our plans and preparations for our upcoming clinical program in HCC.","length":483,"tagName":"p"},{"type":"text","content":""By the end of this year, we expect to have all required appr...